Using integrative proteogenomic analysis, Zhang found that p-mTOR expression level was significantly correlated with improved outcomes in 32 major types of cancer including RCC, which was contradictory to the experimental results (Zhang et al., 2017). The gene discussed is MTOR; the disease is renal cell carcinoma.